Transcriptional Reprogramming and Constitutive PD-L1 Expression in Melanoma Are Associated with Dedifferentiation and Activation of Interferon and Tumour Necrosis Factor Signalling Pathways.
LncRNA
PD-L1
RNA-Seq
dedifferentiation
drug resistance
gene expression
immunotherapy resistance
melanoma
transcriptome
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
24 Aug 2021
24 Aug 2021
Historique:
received:
15
06
2021
revised:
07
08
2021
accepted:
13
08
2021
entrez:
10
9
2021
pubmed:
11
9
2021
medline:
11
9
2021
Statut:
epublish
Résumé
Melanoma is the most aggressive type of skin cancer, with increasing incidence worldwide. Advances in targeted therapy and immunotherapy have improved the survival of melanoma patients experiencing recurrent disease, but unfortunately treatment resistance frequently reduces patient survival. Resistance to targeted therapy is associated with transcriptomic changes and has also been shown to be accompanied by increased expression of programmed death ligand 1 (PD-L1), a potent inhibitor of immune response. Intrinsic upregulation of PD-L1 is associated with genome-wide DNA hypomethylation and widespread alterations in gene expression in melanoma cell lines. However, an in-depth analysis of the transcriptomic landscape of melanoma cells with intrinsically upregulated PD-L1 expression is lacking. To determine the transcriptomic landscape of intrinsically upregulated PD-L1 expression in melanoma, we investigated transcriptomes in melanomas with constitutive versus inducible PD-L1 expression (referred to as PD-L1
Identifiants
pubmed: 34503064
pii: cancers13174250
doi: 10.3390/cancers13174250
pmc: PMC8428231
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Royal Society Te Apārangi
ID : Rutherford Discovery Fellowship
Organisme : Health Research Council of New Zealand
ID : 18-144
Organisme : Cancer Society of New Zealand
ID : 16.06
Références
Nat Commun. 2015 Nov 04;6:8755
pubmed: 26530832
Front Immunol. 2019 Jun 14;10:1337
pubmed: 31258527
Nat Cell Biol. 2020 Jun;22(6):701-715
pubmed: 32424275
Gigascience. 2019 Dec 1;8(12):
pubmed: 31808800
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
Nature. 2009 Nov 5;462(7269):108-12
pubmed: 19847166
Cancer Cell. 2018 May 14;33(5):890-904.e5
pubmed: 29657129
Cell Rep. 2017 May 9;19(6):1189-1201
pubmed: 28494868
Oncotarget. 2017 Jan 24;8(4):6085-6101
pubmed: 28030832
Sci Transl Med. 2013 Aug 28;5(200):200ra116
pubmed: 23986400
Pigment Cell Melanoma Res. 2012 May;25(3):343-53
pubmed: 22336146
J Clin Invest. 2021 Jun 15;131(12):
pubmed: 33914706
Nature. 2012 Oct 18;490(7420):412-6
pubmed: 23051752
Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2301-6
pubmed: 24474804
PLoS One. 2015 Apr 06;10(4):e0123410
pubmed: 25844720
Pigment Cell Res. 2006 Aug;19(4):290-302
pubmed: 16827748
FEBS Lett. 2006 Feb 6;580(3):755-62
pubmed: 16413538
Pigment Cell Res. 2007 Jun;20(3):216-21
pubmed: 17516929
Nat Biotechnol. 2016 May;34(5):525-7
pubmed: 27043002
Cell. 2015 Jan 15;160(1-2):48-61
pubmed: 25594174
Methods Mol Biol. 2016;1418:391-416
pubmed: 27008025
Cancer Discov. 2014 Jul;4(7):816-27
pubmed: 24771846
Immunity. 2018 Mar 20;48(3):434-452
pubmed: 29562194
Nat Commun. 2018 Nov 22;9(1):4931
pubmed: 30467425
Oncotarget. 2017 Feb 28;8(9):15894-15911
pubmed: 28199980
Trends Immunol. 2019 Apr;40(4):328-344
pubmed: 30853334
Cancer Discov. 2017 Nov;7(11):1248-1265
pubmed: 28864476
Cell. 2017 May 4;169(4):636-650.e14
pubmed: 28434617
Front Immunol. 2014 Apr 11;5:156
pubmed: 24782862
Nat Cell Biol. 2020 Jul;22(7):842-855
pubmed: 32514071
Front Immunol. 2018 Jun 21;9:1414
pubmed: 29977240
Cancer Discov. 2018 Aug;8(8):935-943
pubmed: 29899062
Front Pharmacol. 2018 May 22;9:536
pubmed: 29910728
Immunotargets Ther. 2018 Jun 07;7:35-49
pubmed: 29922629
Cancer Discov. 2017 Feb;7(2):188-201
pubmed: 27903500
F1000Res. 2015 Dec 30;4:1521
pubmed: 26925227
Oncogene. 2018 Aug;37(34):4639-4661
pubmed: 29765155
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Nat Commun. 2014 Dec 15;5:5712
pubmed: 25502142
Cancer Res. 2015 Sep 15;75(18):3747-59
pubmed: 26183926
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Genome Biol. 2016 Oct 20;17(1):218
pubmed: 27765066
PLoS One. 2009 Dec 24;4(12):e8461
pubmed: 20041153
Cell. 2015 Sep 10;162(6):1271-85
pubmed: 26359985
Nat Commun. 2017 May 31;8:15440
pubmed: 28561041
Cell. 2015 Aug 27;162(5):961-73
pubmed: 26317465
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Nucleic Acids Res. 2016 May 5;44(8):e71
pubmed: 26704973
Nat Commun. 2015 Apr 09;6:6683
pubmed: 25865119
Nature. 2015 May 21;521(7552):366-70
pubmed: 25799994
Nucleic Acids Res. 2012 May;40(10):e79
pubmed: 22344695
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
Nature. 2014 Apr 3;508(7494):118-22
pubmed: 24670642
Nat Cancer. 2021 Jan;2(1):34-48
pubmed: 33997789
iScience. 2018 Jun 29;4:312-325
pubmed: 30240750
Methods Mol Biol. 2018;1783:35-80
pubmed: 29767357
Nature. 2017 Jun 15;546(7658):431-435
pubmed: 28607484
Cell. 2016 Oct 6;167(2):397-404.e9
pubmed: 27667683
N Engl J Med. 2016 Sep 1;375(9):819-29
pubmed: 27433843
Bioinformatics. 2014 Jul 1;30(13):1814-22
pubmed: 24608764
Cell. 2018 Feb 8;172(4):650-665
pubmed: 29425488
Cell. 2015 Aug 27;162(5):974-86
pubmed: 26317466
Nucleic Acids Res. 2012 Sep 1;40(17):e133
pubmed: 22638577
J Invest Dermatol. 2015 Jul;135(7):1863-1872
pubmed: 25789707